Sutro Biopharma Inc (STRO) extends its cash runway and strengthens partnerships while navigating workforce cuts and ...

Sutro Biopharma (STRO) announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRalphaME-O1 ...

Full Year 2024 Results Key Financial Results Revenue: US$62.0m (down 60% from FY ...

Fintel reports that on March 14, 2025, Wedbush downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Outperform ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 35.19%, which has investors questioning if this is right time to buy.

Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as ...

Sutro Biopharma reported $62 million in 2024 revenue, down from $153.7 million in 2023, and announced a pipeline restructuring.

Sutro Biopharma (STRO) stock drops 14% after deprioritizing ADC program; analysts from Bank of America and Citizens slash ratings in reaction. Read more here.

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...

Sutro Biopharma (NASDAQ:STRO – Get Free Report) was downgraded by research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued on Friday, MarketBeat.com ...